Proteomic  ||| S:0 E:10 ||| JJ
profiling  ||| S:10 E:20 ||| NN
in  ||| S:20 E:23 ||| IN
ovarian  ||| S:23 E:31 ||| JJ
cancer  ||| S:31 E:38 ||| NN
To  ||| S:38 E:41 ||| TO
describe  ||| S:41 E:50 ||| VB
the  ||| S:50 E:54 ||| DT
role  ||| S:54 E:59 ||| NN
of  ||| S:59 E:62 ||| IN
proteomic  ||| S:62 E:72 ||| JJ
profiling  ||| S:72 E:82 ||| NN
in  ||| S:82 E:85 ||| IN
the  ||| S:85 E:89 ||| DT
diagnosis  ||| S:89 E:99 ||| NN
and  ||| S:99 E:103 ||| CC
treatment  ||| S:103 E:113 ||| NN
of  ||| S:113 E:116 ||| IN
ovarian  ||| S:116 E:124 ||| JJ
cancer ||| S:124 E:130 ||| NN
.  ||| S:130 E:132 ||| .
We  ||| S:132 E:135 ||| PRP
report  ||| S:135 E:142 ||| VBP
a  ||| S:142 E:144 ||| DT
thorough  ||| S:144 E:153 ||| JJ
review  ||| S:153 E:160 ||| NN
of  ||| S:160 E:163 ||| IN
the  ||| S:163 E:167 ||| DT
literature ||| S:167 E:177 ||| NN
,  ||| S:177 E:179 ||| ,
ongoing  ||| S:179 E:187 ||| JJ
trials ||| S:187 E:193 ||| NNS
,  ||| S:193 E:195 ||| ,
and  ||| S:195 E:199 ||| CC
our  ||| S:199 E:203 ||| PRP$
group ||| S:203 E:208 ||| NN
's  ||| S:208 E:211 ||| POS
experience  ||| S:211 E:222 ||| NN
with  ||| S:222 E:227 ||| IN
proteomic  ||| S:227 E:237 ||| JJ
profiling  ||| S:237 E:247 ||| NN
for  ||| S:247 E:251 ||| IN
early  ||| S:251 E:257 ||| JJ
detection ||| S:257 E:266 ||| NN
,  ||| S:266 E:268 ||| ,
recurrence ||| S:268 E:278 ||| NN
,  ||| S:278 E:280 ||| ,
and  ||| S:280 E:284 ||| CC
treatment  ||| S:284 E:294 ||| NN
of  ||| S:294 E:297 ||| IN
ovarian  ||| S:297 E:305 ||| JJ
cancer ||| S:305 E:311 ||| NN
.  ||| S:311 E:313 ||| .
Ovarian  ||| S:313 E:321 ||| JJ
cancer  ||| S:321 E:328 ||| NN
remains  ||| S:328 E:336 ||| VBZ
the  ||| S:336 E:340 ||| DT
deadliest  ||| S:340 E:350 ||| JJS
gynecologic  ||| S:350 E:362 ||| JJ
malignancy  ||| S:362 E:373 ||| NN
in  ||| S:373 E:376 ||| IN
the  ||| S:376 E:380 ||| DT
western  ||| S:380 E:388 ||| JJ
world  ||| S:388 E:394 ||| NN
and  ||| S:394 E:398 ||| CC
is  ||| S:398 E:401 ||| VBZ
most  ||| S:401 E:406 ||| RBS
often  ||| S:406 E:412 ||| RB
diagnosed  ||| S:412 E:422 ||| VBN
at  ||| S:422 E:425 ||| IN
a  ||| S:425 E:427 ||| DT
rarely  ||| S:427 E:434 ||| RB
curable  ||| S:434 E:442 ||| JJ
late  ||| S:442 E:447 ||| JJ
stage ||| S:447 E:452 ||| NN
.  ||| S:452 E:454 ||| .
Novel  ||| S:454 E:460 ||| NN
applications  ||| S:460 E:473 ||| NNS
of  ||| S:473 E:476 ||| IN
proteomic  ||| S:476 E:486 ||| JJ
techniques ||| S:486 E:496 ||| NNS
,  ||| S:496 E:498 ||| ,
such  ||| S:498 E:503 ||| JJ
as  ||| S:503 E:506 ||| IN
mass  ||| S:506 E:511 ||| JJ
spectrometry ||| S:511 E:523 ||| NN
,  ||| S:523 E:525 ||| ,
show  ||| S:525 E:530 ||| NN
promise  ||| S:530 E:538 ||| NN
in  ||| S:538 E:541 ||| IN
the  ||| S:541 E:545 ||| DT
quest  ||| S:545 E:551 ||| NN
for  ||| S:551 E:555 ||| IN
reliable  ||| S:555 E:564 ||| JJ
multimodality  ||| S:564 E:578 ||| JJ
screening  ||| S:578 E:588 ||| NN
programs  ||| S:588 E:597 ||| NNS
for  ||| S:597 E:601 ||| IN
the  ||| S:601 E:605 ||| DT
early  ||| S:605 E:611 ||| JJ
detection  ||| S:611 E:621 ||| NN
of  ||| S:621 E:624 ||| IN
ovarian  ||| S:624 E:632 ||| JJ
cancer ||| S:632 E:638 ||| NN
.  ||| S:638 E:640 ||| .
Proteomic  ||| S:640 E:650 ||| JJ
analysis  ||| S:650 E:659 ||| NN
of  ||| S:659 E:662 ||| IN
tissue  ||| S:662 E:669 ||| NN
samples  ||| S:669 E:677 ||| NNS
has  ||| S:677 E:681 ||| VBZ
underscored  ||| S:681 E:693 ||| VBN
the  ||| S:693 E:697 ||| DT
heterogeneity  ||| S:697 E:711 ||| NN
of  ||| S:711 E:714 ||| IN
this  ||| S:714 E:719 ||| DT
disease  ||| S:719 E:727 ||| NN
process ||| S:727 E:734 ||| NN
.  ||| S:734 E:736 ||| .
Development  ||| S:736 E:748 ||| NN
of  ||| S:748 E:751 ||| IN
validated  ||| S:751 E:761 ||| JJ
assays  ||| S:761 E:768 ||| NN
that  ||| S:768 E:773 ||| IN
survey  ||| S:773 E:780 ||| NN
the  ||| S:780 E:784 ||| DT
genetic  ||| S:784 E:792 ||| JJ
and ||| S:792 E:795 ||| CC
/ ||| S:795 E:796 ||| NNP
or  ||| S:796 E:799 ||| CC
proteomic  ||| S:799 E:809 ||| JJ
makeup  ||| S:809 E:816 ||| NN
of  ||| S:816 E:819 ||| IN
an  ||| S:819 E:822 ||| DT
individual  ||| S:822 E:833 ||| JJ
tumor  ||| S:833 E:839 ||| NN
will  ||| S:839 E:844 ||| MD
add  ||| S:844 E:848 ||| VB
greatly  ||| S:848 E:856 ||| RB
to  ||| S:856 E:859 ||| TO
the  ||| S:859 E:863 ||| DT
histological  ||| S:863 E:876 ||| JJ
classification  ||| S:876 E:891 ||| NN
of  ||| S:891 E:894 ||| IN
the  ||| S:894 E:898 ||| DT
tumor  ||| S:898 E:904 ||| NN
and  ||| S:904 E:908 ||| CC
may  ||| S:908 E:912 ||| MD
lead  ||| S:912 E:917 ||| VB
to  ||| S:917 E:920 ||| TO
different  ||| S:920 E:930 ||| JJ
treatment  ||| S:930 E:940 ||| NN
approaches  ||| S:940 E:951 ||| VBZ
tailored  ||| S:951 E:960 ||| VBN
to  ||| S:960 E:963 ||| TO
the  ||| S:963 E:967 ||| DT
unique  ||| S:967 E:974 ||| JJ
expression  ||| S:974 E:985 ||| NN
pattern  ||| S:985 E:993 ||| NN
of  ||| S:993 E:996 ||| IN
each  ||| S:996 E:1001 ||| DT
individual  ||| S:1001 E:1012 ||| JJ
patient ||| S:1012 E:1019 ||| NN
.  ||| S:1019 E:1021 ||| .
As  ||| S:1021 E:1024 ||| IN
novel  ||| S:1024 E:1030 ||| NN
agents  ||| S:1030 E:1037 ||| NNS
that  ||| S:1037 E:1042 ||| IN
disrupt  ||| S:1042 E:1050 ||| JJ
signal  ||| S:1050 E:1057 ||| NN
propagation  ||| S:1057 E:1069 ||| NNS
develop ||| S:1069 E:1076 ||| VBP
,  ||| S:1076 E:1078 ||| ,
proteomic  ||| S:1078 E:1088 ||| JJ
profiling  ||| S:1088 E:1098 ||| NN
by  ||| S:1098 E:1101 ||| IN
reverse-phase  ||| S:1101 E:1115 ||| JJ
protein  ||| S:1115 E:1123 ||| NN
arrays  ||| S:1123 E:1130 ||| NNS
can  ||| S:1130 E:1134 ||| MD
characterize  ||| S:1134 E:1147 ||| VB
the  ||| S:1147 E:1151 ||| DT
in-tumor  ||| S:1151 E:1160 ||| JJ
efficacy  ||| S:1160 E:1169 ||| NN
of  ||| S:1169 E:1172 ||| IN
the  ||| S:1172 E:1176 ||| DT
agent  ||| S:1176 E:1182 ||| NN
by  ||| S:1182 E:1185 ||| IN
quantification  ||| S:1185 E:1200 ||| NN
of  ||| S:1200 E:1203 ||| IN
the  ||| S:1203 E:1207 ||| DT
changes  ||| S:1207 E:1215 ||| NNS
in  ||| S:1215 E:1218 ||| IN
expression  ||| S:1218 E:1229 ||| NN
levels  ||| S:1229 E:1236 ||| NNS
of  ||| S:1236 E:1239 ||| IN
activated  ||| S:1239 E:1249 ||| JJ
proteins ||| S:1249 E:1257 ||| NNS
.  ||| S:1257 E:1259 ||| .
Together ||| S:1259 E:1267 ||| RB
,  ||| S:1267 E:1269 ||| ,
better  ||| S:1269 E:1276 ||| JJR
understanding  ||| S:1276 E:1290 ||| NN
of  ||| S:1290 E:1293 ||| IN
the  ||| S:1293 E:1297 ||| DT
potential  ||| S:1297 E:1307 ||| JJ
diagnostic  ||| S:1307 E:1318 ||| JJ
and  ||| S:1318 E:1322 ||| CC
therapeutic  ||| S:1322 E:1334 ||| JJ
targets  ||| S:1334 E:1342 ||| NNS
followed  ||| S:1342 E:1351 ||| VBN
with  ||| S:1351 E:1356 ||| IN
proof-of-target  ||| S:1356 E:1372 ||| JJ
effect  ||| S:1372 E:1379 ||| NN
will  ||| S:1379 E:1384 ||| MD
lead  ||| S:1384 E:1389 ||| VB
to  ||| S:1389 E:1392 ||| TO
rational  ||| S:1392 E:1401 ||| JJ
combinations  ||| S:1401 E:1414 ||| NNS
of  ||| S:1414 E:1417 ||| IN
novel  ||| S:1417 E:1423 ||| NN
therapy  ||| S:1423 E:1431 ||| NN
and  ||| S:1431 E:1435 ||| CC
improve  ||| S:1435 E:1443 ||| VB
individual  ||| S:1443 E:1454 ||| JJ
ovarian  ||| S:1454 E:1462 ||| JJ
cancer  ||| S:1462 E:1469 ||| NN
patient  ||| S:1469 E:1477 ||| NN
outcome ||| S:1477 E:1484 ||| NN
.  ||| S:1484 E:1486 ||| .
